US2003153528A1PendingUtilityA1

Hemostatic bone wax composition

62
Priority: Nov 13, 2001Filed: Oct 9, 2002Published: Aug 14, 2003
Est. expiryNov 13, 2021(expired)· nominal 20-yr term from priority
Inventors:Melvin E. Levinson
A61K 31/715A61B 17/0057A61F 13/00A61F 2013/00412A61F 2013/00472A61L 2400/04
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A hemostatic composition for effecting hemostasis at a hemorrhaging site comprises a hemostatically effective amount of cationic substance and a wax base, wherein the cationic substance is substantially uniformly dispersed in the bone wax base. The method of preparing the hemostatic composition includes admixing an aqueous solution of a cationic substance and a bone wax, and freeze-drying the mixture to remove substantially all of the water to yield a viscous water soluble composition of fine particles of cationic which is substantially uniformly dispersed throughout the bone wax base. The method for effecting hemostasis comprises making the hemostatic composition and applying a hemostatically effective amount of the hemostatic composition to the hemorrhaging site.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A hemostatic composition comprising: 
 a hemostatically effective amount of hemostatic cationic substance; and    a base in a form of wax, and wherein said hemostatic cationic substance is substantially uniformly dispersed in said base.    
     
     
         2 . The composition of  claim 1 , wherein the hemostatic cationic substance comprises a biopolymer of glucosamine,  
     
     
         3 . The composition of  claim 2 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine.  
     
     
         4 . The composition of  claim 2 , wherein the biopolymer of glucosamine is poly-D-glucosamine.  
     
     
         5 . The composition of  claim 2 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine.  
     
     
         6 . The composition of  claim 2 , wherein the biopolymer of glucosamine is an acetate salt of poly-D-glucosamine.  
     
     
         7 . The composition of  claim 2 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and poly-D-glucosamine.  
     
     
         8 . The composition of  claim 2 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine.  
     
     
         9 . The composition of  claim 2 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.  
     
     
         10 . The composition of  claim 2 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.  
     
     
         11 . The composition of  claim 1 , wherein said base is bone wax.  
     
     
         12 . The composition of  claim 1 , wherein said base is water-soluble.  
     
     
         13 . The composition of  claim 1  further includes an anti-microbial material.  
     
     
         14 . A method for making a hemostatic composition comprising: 
 mixing a hemostatically effective amount of hemostatic cationic substance and a base, wherein said base is in a form of wax.    
     
     
         15 . The method of  claim 14 , wherein the hemostatic cationic substance comprises a biopolymer of glucosamine,  
     
     
         16 . The method of  claim 15 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine.  
     
     
         17 . The method of  claim 15 , wherein the biopolymer of glucosamine is poly-D-glucosamine.  
     
     
         18 . The method of  claim 15 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine.  
     
     
         19 . The method of  claim 15 , wherein the biopolymer of glucosamine is an acetate salt of poly-D-glucosamine.  
     
     
         20 . The method of  claim 15 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and poly-D-glucosamine.  
     
     
         21 . The method of  claim 15 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine.  
     
     
         22 . The method of  claim 15 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.  
     
     
         23 . The method of  claim 15 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.  
     
     
         24 . The method of  claim 14 , wherein said base is bone wax.  
     
     
         25 . The method of  claim 14 , wherein said base is water-soluble.  
     
     
         26 . The method of  claim 14  further includes a step of mixing an anti-microbial material in said composition.  
     
     
         27 . A method for effecting hemostatic composition at a hemorrhaging site in a mammal comprising: 
 A). forming a hemostatic composition by mixing a hemostatically effective amount of hemostatic cationic substance and a base, wherein said base is in form of wax; and    B). applying a hemostatic effective amount of said hemostatic composition to the hemorrhaging site of the mammal.    
     
     
         28 . The method of  claim 27 , wherein the hemostatic cationic substance comprises a biopolymer of glucosamine,  
     
     
         29 . The method of  claim 28 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine.  
     
     
         30 . The method of  claim 28 , wherein the biopolymer of glucosamine is poly-D-glucosamine.  
     
     
         31 . The method of  claim 28 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine.  
     
     
         32 . The method of  claim 28 , wherein the biopolymer of glucosamine is an acetate salt of poly-D-glucosamine.  
     
     
         33 . The method of  claim 28 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and poly-D-glucosamine.  
     
     
         34 . The method of  claim 28 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine.  
     
     
         35 . The method of  claim 28 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.  
     
     
         36 . The method of  claim 28 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.  
     
     
         37 . The method of  claim 27 , wherein said base is bone wax.  
     
     
         38 . The method of  claim 27  further includes maintaining pressure for a predetermined time on the hemorrhaging site after applying said hemostatic composition to the hemorrhaging site of the mammal.

Join the waitlist — get patent alerts

Track US2003153528A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.